Announcements Trials
Browse Landscape

Phase

Phase 1/2 1Phase 1 1

Status

Recruiting 6Suspended 2

Sponsor Class

NIH 1INDUSTRY 1

Study Type

Interventional 2

Sponsor

Cancer Type

Other hematologic neoplasm 1Myeloid 1Gastrointestinal 1

Conditions

Recurrence 1Pancreatic Neoplasms 1Myelodysplastic Syndromes 1Leukemia, Myeloid, Acute 1Hereditary Sensory and Autonomic Neuropathies 1

Interventions

Specimen Handling 34Magnetic Resonance Spectroscopy 22Biopsy 20Cyclophosphamide 11venetoclax 7Nivolumab 6Azacitidine 6pembrolizumab 5Etoposide 5Cisplatin 5Bevacizumab 5fludarabine phosphate 4fludarabine 4Vincristine 4Taxes 4Surgical Procedures, Operative 4Radiotherapy, Intensity-Modulated 4Radiosurgery 4Radiation 4Doxorubicin 4Cetuximab 4durvalumab 3decitabine and cedazuridine drug combination 3X-Rays 3Tacrolimus 3Surveys and Questionnaires 3Prednisone 3Platinum 3Leucovorin 3Irinotecan 3

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

2 trials
RecentStart dateEnrollment
Suspended × CA-4948 × 1 year × Clear all
NCT05685602 2026-05-18

CA-4948 Added to Standard Chemotherapy to Treat Metastatic or Unresectable Pancreatic Cancer

National Cancer Institute (NCI)

Phase 1 Suspended
43 enrolled
Gastrointestinal

Pancreatic Neoplasms

NCT04278768 2026-03-19

Dose Escalation/ Expansion Study of CA-4948 as Monotherapy in Patients With Acute Myelogenous Leukemia (AML) or Myelodysplastic Syndrome (MDS)

Curis, Inc.

Phase 1/2 Suspended
366 enrolled
MyeloidOther hematologic neoplasm

Myelodysplastic Syndromes, Hereditary Sensory and Autonomic Neuropathies, Recurrence, Leukemia, Myeloid, Acute

Data powered by HemOnc (CC BY 4.0) Colophon âš¡